Strengths
Nu.Q® Technology offers innovative blood-based tests that provide high specificity (97%) in detecting systemic cancers, which is a significant advantage over traditional diagnostic methods.
The proprietary Nucleosomics™ platform allows for rapid epigenetic profiling, enhancing the speed and efficiency of disease detection.
VolitionRx has a robust intellectual property portfolio, which protects its unique technologies and provides a competitive edge in the diagnostics market.
The company is positioned as a leader in epigenetics, focusing on non-invasive diagnostic solutions that appeal to both human and veterinary medicine sectors.
The commitment to improving patient outcomes through advanced diagnostic technologies is a core value that resonates with healthcare professionals and researchers.
VolitionRx's tests are cost-effective and easy to use, making them accessible for routine blood tests in both clinical and research settings.
The company has established strong relationships with leading academic institutions and pharmaceutical companies, enhancing its credibility and market reach.
The ongoing development of new assays and technologies indicates a strong focus on innovation and adaptability in a rapidly evolving healthcare landscape.